anti-SARS-CoV-2 spike protein antibody vaccine (Centenary Institute Cancer/University of Sydney/University of Technology Sydney/Kirby Institute/ExcellGene)

N/A

Report date: 2025/01/26 17:59:40

Base Information

Drug Nameanti-SARS-CoV-2 spike protein antibody vaccine (Centenary Institute Cancer/University of Sydney/University of Technology Sydney/Kirby Institute/ExcellGene)
Drug Alias Namesingle-shot protein based vaccine (University of Sydney/Centenary Institute/University of Technology Sydney/Kirby Institute/ExcellGene)
ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCentenary Institute Cancer Medicine & Cell Biology
China Registration ClassN/A

Develop Information

Active CompaniesCentenary Institute Cancer Medicine & Cell BiologyUniversity Of Technology, SydneyExcellGene SA +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A